Abstract
For many years neuroleptic drugs have been used as the only rational pharmacotherapy of schizophrenia. Over these years, it has been demonstrated that there is a very close correlation between the ability of neuroleptics to control psychosis and the degree of dopamine D2 receptor affinity [1,2]. Recently several dopamine receptor subtypes have been identified by means of molecular biology cloning techniques [3,4]. Currently two major families of dopamine receptor genes have been identified, a D1 family comprising D1A and D5 receptors, and a D2 family comprising D2-long, D2-short, D3 and D4 subtypes. Work in this area has further confirmed that neuroleptic drugs share the ability to block receptors within the D2 family. Some, but not all of the neuroleptics, interact with the D1 receptors.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Creese I, Burt DR, and Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976;192:481–483.
Seeman P. Brain dopamine receptors. Pharmacol. Rev. 1980;32:229–313.
Civelli O, Bunzow JR, Grandy DK, Zhou Q-Y and Van Tol HHM. Molecular biology of the dopamine receptors. Eur. J. Pharmacol. Mol. Pharmacol. 1991;207:277–286.
Sibley DR and Monsma FJ Jr. Molecular biology of dopamine receptors. Trends Pharmacol. Sci. 1992;13:61–69.
Hyttel J. SCH 23390 - the first selective dopamine D1 antagonist. Euro. J. Pharmacol. 1983;91:153–154.
Christensen AV, Arnt J, Hyttel J, Larsen JJ and Svendsen O. Pharmacological effects of a specific dopamine D1 antagonist SCH 23390 in comparison with neuroleptics. Life. Sci. 1984;34:1529–1540.
lorio LC, Barnett A, Leitz FH, Houser VP and Korduba CA. SCH 23390: a potential benzazepine antiphychotic with unique interactions on dopamine systems. J. Pharmacol. Exp. Ther. 1983;226:462–468.
Nielsen EB and Andersen PH. Dopamine receptor occupancy in vivo: behavioral correlates using NNC-112, NNC-687 and NNC-756, new selective dopamine D1 receptor antagonists. Eur. J. Pharmacol. 1992;219:35–44.
Wachtel SR, Hu X-T, Galloway MP and White FJ. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems. Synapse 1989;4:327–346.
White FJ, Bednarz LM, Wachtel SR, Hjorth S and rooderson RJ. Is stimulation of both D1 and D2 receptors necessary for the expression of dopamine-mediated behaviors. Pharmacol. Biochem. Behav. 1988;30:189–193.
Clark D. and White FJ. D1 dopamine receptor - the search for a function: a critical evaluation of the D1/D2 dopamine receptor classification and its functional implications. Synapse. 1987;1:347–388.
White FJ. D-1 dopamine receptor stimulation enables the inhibition of nucleus accumbens neurons by a D-2 receptor agonist. Eur. J. Pharmacol. 1987;135:101–105.
Arnt J, Hyttel J., and Perregaard J. Dopamine D1 receptor agonists combined with the selective D2 agonist quinpirole facilitate the expression of oral stereotyped behaviour in rats. Eur. J. Pharmacol. 1987;133:137–145.
Arnt J and Perregaard J. Synergistic interaction between dopamine D1 and D2 receptor agonists: circling behaviour of rats with hemitransection. Eur. J. Pharmacol. 1987;143:45–53.
Arnt J. Behavioural stimulation is induced by separate dopamine D1 and D2 receptor sites in reserpine-pretreated but not in normal rats. Eur. J. Pharmacol. 1985; 133:79–88.
Ellenbroek BA, Willemen APM and Cools AR. Are antagonists of dopamine D1 receptors drugs that attenuate both positive and negative symptoms of schizophrenia? Neuropsychopharmacology. 1989;2:291–199.
Ellenbroek BA and, Cools AR. Animal models with construct validity for schizophrenia. Behav. Pharmacol. 1990;1:469–490.
Memo M, Kleinman JE and Hanbauer I. Coupling of dopamine D1 recognition sites with adenylate cyclase in nuclei accumbens and caudatus of schizophrenics. Science 1983;221:1304–1307.
Farde L, Wiesel F-A, Hall H, Halldin C and Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs, Arch. Gen. Psychiat. 1988;145:71.
Farde L, Wiesel F-A, Nordstroem A-L and Sedvall G. D1 and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychomarcology. 1989;99:S28.
Farde L, Nordstroem A-L, Wiesel F-A, Pauli S, Halldin C and Sedvall G. PET-analysis of central D1 and D2-dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine relation to extrapyramidal side effects. Arch. Gen. Psychiatry. 1992;49:538–544.
Farde L and Nordstroem A-L. PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients. Br. J. Psychiatry. 1992; 160 Suppl. 17:30–33.
Farde L. Selective D1 and D2-dopamine receptor blockade both induce akathisia in humas - a PET study with [11C]SCH23390 and [11C]raclopride. Psychopharmacology. 1992;107:23–29.
Andersen PH, Groenvald FC, Hohlweg R, Hansen LB, Guddal E, Braestrup C and Nielsen EB. NNC-112, NNC-687 and NNC-756, new selective and highly potent dopamine D1 receptor antagonists. European Journal of Pharmacology. 1992;219:45–52.
Halldin C, Foged C, Farde L, Karlsson P, Hansen K, Groenvald F, Swahn C-G, Hall H and Sedvall G. [11C]NNC-687 and [11C]NNC-756, dopamine D1 receptor ligands. Preparation, autoradiography and PET investigation in monkey. Nucl. Med. Biol. 1993;8:945–953.
Karlsson P, Farde L, Halldin C, Sedvall G, Foged C, Hansen KT and Skrumsager B. [11C]NNC-687 and [11C]NNC-756 as radioligands for PET-determination of central D1-dopamine receptors. Psychopharmacol. 1993;133:149–156.
Karlsson P, Farde L, Halldin C, Sedvall G, Ynddal L, and Sloth-Nielsen M. Oral administration of NNC-756 - a placebo controlled PET study of D1-dopamine receptor occupancy and pharmacodynamics in man. Psychopharmacol. (submitted 1994)
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Foged, C. et al. (1995). PET in the Development of Dopamine D1 Antagonists as New Potential Antipsychotic Drugs. In: Comar, D. (eds) PET for Drug Development and Evaluation. Developments in Nuclear Medicine, vol 26. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-0429-6_7
Download citation
DOI: https://doi.org/10.1007/978-94-011-0429-6_7
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-4191-1
Online ISBN: 978-94-011-0429-6
eBook Packages: Springer Book Archive